82,891
edits
Central counterparty clearing house: Difference between revisions
Central counterparty clearing house (view source)
Revision as of 08:37, 30 April 2019
, 30 April 2019no edit summary
Amwelladmin (talk | contribs) m (Amwelladmin moved page Central Counterparty Clearing to Central counterparty clearing house) |
Amwelladmin (talk | contribs) No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{anat|brokerage}}A topic of great interest to you if your interests lie in things like {{emir}}. | {{anat|brokerage|}} | ||
A topic of great interest to you if your interests lie in things like {{emir}}. | |||
{{Quote|"By and large, derivatives are traded in OTC markets, where dealers trade bilaterally with each other and with clients. If those market participants do not use a {{ccp|central counterparty}} (CCP), this exposes both parties to bilateral counterparty credit risk, in particular when derivatives positions are held over long maturities. These exposures are significant: the aggregate credit exposure related to derivative holdings for the top five US banks has been estimated to be over US$1 trillion. {{ccp|Transparency}} in these markets is generally low, so it is difficult to know the exact nature of counterparty credit exposures at both the individual and the global level. During the 2007–09 financial crisis, lack of transparency, combined with increased concerns about counterparty credit risk led to a significant reduction in liquidity." <br> | {{Quote|"By and large, derivatives are traded in OTC markets, where dealers trade bilaterally with each other and with clients. If those market participants do not use a {{ccp|central counterparty}} (CCP), this exposes both parties to bilateral counterparty credit risk, in particular when derivatives positions are held over long maturities. These exposures are significant: the aggregate credit exposure related to derivative holdings for the top five US banks has been estimated to be over US$1 trillion. {{ccp|Transparency}} in these markets is generally low, so it is difficult to know the exact nature of counterparty credit exposures at both the individual and the global level. During the 2007–09 financial crisis, lack of transparency, combined with increased concerns about counterparty credit risk led to a significant reduction in liquidity." <br> | ||
::- ''Thoughts on determining central clearing eligibility of OTC derivatives'' - Bank of England Financial Stability Paper no. 14 - March 2012. | ::- ''Thoughts on determining central clearing eligibility of OTC derivatives'' - Bank of England Financial Stability Paper no. 14 - March 2012.}} | ||
}} | |||
===Summary=== | ===Summary=== | ||
| Line 13: | Line 12: | ||
**'''Europe''':In Europe this is part of the [[European Market Infrastructure Regulation]] ({{tag|EMIR}}) process led by the [[European Commission]]. | **'''Europe''':In Europe this is part of the [[European Market Infrastructure Regulation]] ({{tag|EMIR}}) process led by the [[European Commission]]. | ||
*'''Timing''': G20 Mandated that all standardised OTC derivative contracts be traded on exchanges or electronic trading platforms, where appropriate, and cleared through central counterparties by the end of 2012. There have been delays in both rule making and implementation across G20 jurisdictions. many jurisdictions have not yet fully defined the nature of either the central clearing or the trading obligation — which products are in scope; which factors will be used to determine the scope. | *'''Timing''': G20 Mandated that all standardised OTC derivative contracts be traded on exchanges or electronic trading platforms, where appropriate, and cleared through central counterparties by the end of 2012. There have been delays in both rule making and implementation across G20 jurisdictions. many jurisdictions have not yet fully defined the nature of either the central clearing or the trading obligation — which products are in scope; which factors will be used to determine the scope. | ||
===See also=== | ===See also=== | ||
*{{crrprov|306(1)}} - [[regulatory capital]] treatment for {{crrprov|CCP}}s under {{crr}}. | *{{crrprov|306(1)}} - [[regulatory capital]] treatment for {{crrprov|CCP}}s under {{crr}}. | ||
__NOTOC__ | __NOTOC__ | ||